Additive hazards models with latent treatment effectiveness lag time
具有潜在治疗生效滞后时间的加性风险模型AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要明确以治疗效应估计为目标,并应用于随机临床试验,直接关联因果推断。
具有潜在治疗生效滞后时间的加性风险模型AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
In many clinical trials for evaluating treatment efficacy, it is believed that there may exist latent treatment effectiveness lag times after which medical treatment procedure or chemical compound would be in full effect. In this paper, semiparametric regression models are proposed and studied for estimating the treatment effect accounting for such latent lag times. The new models take advantage of the invariant property of the additive hazards model in marginalising over an additive latent variable; parameters in the models are thus easily estimated and interpreted, while the flexibility of not having to specify the baseline hazard function is preserved. Monte Carlo simulation studies demonstrate the appropriateness of the proposed semiparametric estimation procedure. The methodology is applied to data collected in a randomised clinical trial, which evaluates the efficacy of biodegradable carmustine polymers for treatment of recurrent brain tumours.